後期慢性腎臓病治療薬の世界市場レポート2024年

後期慢性腎臓病治療薬の市場規模は、今後数年間で急速に成長すると予想されています。 2028年には11.2%の年間複合成長率（CAGR）で109億4,000万米ドルに成長すると予想されます。予測期間で予想される成長は、医療費の増加、精密医療アプローチの導入、再生医療への注目の高まり、患者中心のケアの重視の高まり、意識向上を目的とした世界の取り組みなど、いくつかの要因によるものと考えられます。腎臓の病気について。予測期間中に予想される主要動向には、再生医療治療の拡大、慢性腎臓病（CKD）管理のための遠隔医療サービスの増加、併用療法の開発、早期介入戦略への注目、バイオマーカーベースの治療への関心の高まりが含まれます。診断。

後期慢性腎臓病治療薬市場の予想される成長は、慢性腎臓病の有病率の高さによって促進されると予想されます。慢性腎臓病には、腎臓の構造と機能に影響を与えるさまざまな状態が含まれます。後期慢性腎臓病の治療薬は、血圧を制御し、タンパク質の損失を減らし、症状を管理して腎機能障害の進行を止め、合併症を防ぐのに非常に重要です。 2022年 7月の時点で、米国疾病管理予防センターは、米国の約15%、または3,700万人が腎臓病に罹患していると報告しました。有病率は年齢層によって異なり、2021年には45～64歳の有病率が12%であったのに対し、18～44歳の有病率は6%と最も低かった。その結果、慢性腎臓病の有病率の上昇が主要要因となっています。

糖尿病の高い有病率は、後期慢性腎臓病治療薬市場の成長を促進すると予想されるもう1つの重要な要因です。血糖値の上昇を特徴とする糖尿病は、腎臓を含むさまざまな臓器に深刻な損傷を与えるリスクをもたらします。糖尿病は、特に後期において、慢性腎臓病の発症の危険因子であることが十分に確立されています。糖尿病の有病率が世界的に増加するのに伴い、後期慢性腎臓病の発生率も比例して増加すると予想されています。たとえば、Diabetes UKは、2023年 4月の時点で、英国では430万人以上が糖尿病を抱えており、さらに85万人が糖尿病であるにもかかわらず未診断のままである可能性があると報告しています。前年と比較して、これらの登録数は14万8,591件増加しました。注目すべきことに、英国では血糖値の測定値に基づいて約240万人が2型糖尿病を発症するリスクが高いとされています。したがって、糖尿病の高い有病率は、後期慢性腎臓病治療薬市場の成長を促進する重要な要因です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の後期慢性腎臓病治療薬市場の促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の後期慢性腎臓病治療薬の市場規模実績と成長、2018～2023年
• 世界の後期慢性腎臓病治療薬市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

• 世界の後期慢性腎臓病治療薬市場、製品タイプ別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• カルシウム模倣薬
• ビタミンD
• ステロール
• カリウム結合剤
• カルシウムベースのリン酸塩結合剤
• 世界の後期慢性腎臓病治療薬市場、適応症別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 後期慢性腎臓病による副甲状腺機能亢進症
• 後期慢性腎臓病による高リン血症
• 後期慢性腎臓病による高カリウム血症
• 世界の後期慢性腎臓病治療薬市場、流通チャネル別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 病院薬局
• オンライン薬局
• 小売薬局

第7章 地域と国の分析

• 世界の後期慢性腎臓病治療薬市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
• 世界の後期慢性腎臓病治療薬市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 後期慢性腎臓病治療薬市場の競合情勢
• 後期慢性腎臓病治療薬市場の企業プロファイル
  • Pfizer Inc.
  • Johnson &Johnson
  • AbbVie Inc.
  • Bayer AG
  • Novartis AG

第31章 その他の大手と革新的な企業

• Sanofi SA
• Bristol-Myers Squibb Company
• AstraZeneca plc
• Eli Lilly and Company
• CH Boehringer Sohn AG &Co. KG
• Amgen Inc.
• Novo Nordisk A/S
• Teva Pharmaceutical Industries Ltd.
• Otsuka Pharmaceutical Co. Ltd.
• Takeda Pharmaceutical Company Limited
• Kyowa Kirin Co Ltd.
• Vifor Pharma Management Ltd.
• OPKO Health Inc.
• Evotec SE
• Ionis Pharmaceuticals Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の展望と潜在性分析

第36章 付録

Late-stage chronic kidney disease drugs are medications designed to treat end-stage chronic kidney disease, aiming to improve patients' quality of life by arresting the progression of the disease and, in some cases, preventing or delaying the need for dialysis or a kidney transplant.

The primary product types of late-stage chronic kidney disease drugs include calcimimetics, vitamin D, sterols, potassium binders, and calcium-based phosphate binders. Calcimimetics, for instance, constitute a class of medications that enhance signaling and reduce parathyroid hormone (PTH) levels by activating the calcium-sensing receptor allosterically. These drugs address various indications related to late-stage chronic kidney disease, such as hyperparathyroidism, hyperphosphatemia, and hyperkalemia. The distribution channels for these drugs typically include hospital pharmacies, online pharmacies, and retail pharmacies.

The late stage chronic kidney disease drugs market research report is one of a series of new reports from The Business Research Company that provides late stage chronic kidney disease drugs market statistics, including late stage chronic kidney disease drugs industry global market size, regional shares, competitors with a late stage chronic kidney disease drugs market share, detailed late stage chronic kidney disease drugs market segments, market trends and opportunities, and any further data you may need to thrive in the late stage chronic kidney disease drugs industry. This late stage chronic kidney disease drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The late stage chronic kidney disease drugs market size has grown rapidly in recent years. It will grow from $6.38 billion in 2023 to $7.16 billion in 2024 at a compound annual growth rate (CAGR) of 12.2%. The growth observed in the historic period can be attributed to several factors, including advancements in diagnostic capabilities, an aging population, an increased prevalence of diabetes and hypertension, a heightened awareness of kidney diseases, and the expansion of pharmaceutical research and development.

The late stage chronic kidney disease drugs market size is expected to see rapid growth in the next few years. It will grow to $10.94 billion in 2028 at a compound annual growth rate (CAGR) of 11.2%. The anticipated growth in the forecast period can be attributed to several factors, including the increasing healthcare expenditure, the adoption of precision medicine approaches, a growing focus on regenerative medicine, a heightened emphasis on patient-centered care, and global initiatives aimed at raising awareness about kidney diseases. Major trends expected in the forecast period encompass the expansion of regenerative medicine therapies, the rise in telemedicine services for chronic kidney disease (CKD) management, the development of combination therapies, a focus on early intervention strategies, and a growing interest in biomarker-based diagnostics.

The anticipated growth in the late-stage chronic kidney disease drug market is expected to be propelled by the high prevalence of chronic kidney diseases. Chronic kidney diseases encompass a diverse range of conditions impacting the structure and function of the kidneys. Late-stage chronic kidney disease drugs are crucial in controlling blood pressure, reducing protein loss, and managing symptoms to halt the progression of kidney impairment and prevent complications. As of July 2022, the Centers for Disease Control and Prevention reported that approximately 15%, or 37 million people in the US, were affected by kidney disease. The prevalence varied across age groups, with individuals aged 45-64 experiencing a 12% prevalence, while those between 18 and 44 had the lowest majority at 6% in 2021. Consequently, the rising prevalence of chronic kidney disease serves as a key driver for the growth of the late-stage chronic kidney disease drug market.

The high prevalence of diabetes is another significant factor expected to drive the growth of the late-stage chronic kidney disease drug market. Diabetes, characterized by elevated blood glucose levels, poses a risk for serious damage to various organs, including the kidneys. Diabetes is a well-established risk factor for the development of chronic kidney disease, especially in its later stages. With the global increase in the prevalence of diabetes, the incidence of late-stage chronic kidney disease is also expected to rise proportionally. For example, as of April 2023, Diabetes UK reported that more than 4.3 million people in the UK are living with diabetes, and an additional 850,000 individuals may have diabetes but remain undiagnosed. Compared to the previous year, these registration numbers increased by 148,591. Notably, almost 2.4 million people in the UK have an elevated risk of developing type 2 diabetes based on blood sugar readings. Consequently, the high prevalence of diabetes is a significant factor driving the growth of the late-stage chronic kidney disease drug market.

Product innovation emerges as a prominent trend gaining traction in the late-stage chronic kidney disease drug market, with major companies actively developing new drugs to maintain their market positions. For example, in February 2022, Bayer, a leading Germany-based pharmaceutical and biotechnology company, introduced Kerendia (finerenone) in India. Finerenone, a first-in-class non-steroidal, selective mineralocorticoid receptor antagonist, is recommended for patients with type two diabetes and chronic renal disease. The drug works by preventing the overactivation of the mineralocorticoid receptor (MR), believed to be a factor in the development of chronic kidney disease (CKD) and cardiovascular harm.

Strategic collaborations are another key focus for major companies operating in the late-stage chronic kidney disease drug market, aiming to create synergies for advancing precision medicines in this field. In March 2021, Evotec SE, a Germany-based drug discovery and development company, collaborated with Chinook Therapeutics, a Canada-based clinical-stage biopharmaceutical company. This strategic partnership is dedicated to discovering and developing novel precision medicines for chronic kidney diseases. By leveraging Evotec's extensive molecular datasets from hundreds of patients with diverse underlying etiologies of chronic kidney diseases, the collaboration aims to identify, characterize, and validate novel mechanisms, ultimately leading to the discovery and development of precision therapies.

In January 2023, AstraZeneca, a UK-based biopharmaceutical and biotechnology company, acquired CinCor Pharma Inc. for $1.3 billion. This strategic acquisition strengthens AstraZeneca's cardiorenal pipeline by adding CinCor's potential medication, baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) designed to treat chronic kidney disorders. CinCor Pharma Inc., a US-based clinical-stage biopharmaceutical company, is the developer of baxdrostat. The acquisition enhances AstraZeneca's position in the late-stage chronic kidney disease drug market.

Major companies operating in the late stage chronic kidney disease drugs market report are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Amgen Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Kyowa Kirin Co Ltd., OPKO Health Inc., Evotec SE, Ionis Pharmaceuticals Inc., Akebia Therapeutics Inc., Ardelyx Inc., Concert Pharmaceuticals Inc., Pharmaxis Limited, Deltanoid Pharmaceuticals Inc., Liminal BioSciences Inc., Chinook Therapeutics Inc., Allena Pharmaceuticals Inc., Shield Therapeutics PLC, Shire plc.

North America was the largest region in the late stage chronic kidney disease drugs market in 2023. The regions covered in the late stage chronic kidney disease drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the late stage chronic kidney disease drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The late-stage chronic kidney disease drugs market consists of sales of angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB), and erythropoietin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Late Stage Chronic Kidney Disease Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on late stage chronic kidney disease drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for late stage chronic kidney disease drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The late stage chronic kidney disease drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Product Type: Calcimimetics; Vitamin D; Sterols; Potassium Binders; Calcium-Based Phosphate Binders
• 2) By Indication Type: Late Stage Chronic Kidney Disease Induced Hyperparathyroidism; Late Stage Chronic Kidney Disease Induced Hyperphosphatemia; Late Stage Chronic Kidney Disease Induced Hyperkalemia
• 3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; AbbVie Inc.; Bayer AG; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Late Stage Chronic Kidney Disease Drugs Market Characteristics

3. Late Stage Chronic Kidney Disease Drugs Market Trends And Strategies

4. Late Stage Chronic Kidney Disease Drugs Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Late Stage Chronic Kidney Disease Drugs Market Size and Growth

• 5.1. Global Late Stage Chronic Kidney Disease Drugs Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Late Stage Chronic Kidney Disease Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Late Stage Chronic Kidney Disease Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Late Stage Chronic Kidney Disease Drugs Market Segmentation

• 6.1. Global Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Calcimimetics
• Vitamin D
• Sterols
• Potassium Binders
• Calcium-Based Phosphate Binders
• 6.2. Global Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Late Stage Chronic Kidney Disease Induced Hyperparathyroidism
• Late Stage Chronic Kidney Disease Induced Hyperphosphatemia
• Late Stage Chronic Kidney Disease Induced Hyperkalemia
• 6.3. Global Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

7. Late Stage Chronic Kidney Disease Drugs Market Regional And Country Analysis

• 7.1. Global Late Stage Chronic Kidney Disease Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Late Stage Chronic Kidney Disease Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market

• 8.1. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Late Stage Chronic Kidney Disease Drugs Market

• 9.1. China Late Stage Chronic Kidney Disease Drugs Market Overview
• 9.2. China Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Late Stage Chronic Kidney Disease Drugs Market

• 10.1. India Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Late Stage Chronic Kidney Disease Drugs Market

• 11.1. Japan Late Stage Chronic Kidney Disease Drugs Market Overview
• 11.2. Japan Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Late Stage Chronic Kidney Disease Drugs Market

• 12.1. Australia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Late Stage Chronic Kidney Disease Drugs Market

• 13.1. Indonesia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Late Stage Chronic Kidney Disease Drugs Market

• 14.1. South Korea Late Stage Chronic Kidney Disease Drugs Market Overview
• 14.2. South Korea Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Late Stage Chronic Kidney Disease Drugs Market

• 15.1. Western Europe Late Stage Chronic Kidney Disease Drugs Market Overview
• 15.2. Western Europe Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Late Stage Chronic Kidney Disease Drugs Market

• 16.1. UK Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Late Stage Chronic Kidney Disease Drugs Market

• 17.1. Germany Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Late Stage Chronic Kidney Disease Drugs Market

• 18.1. France Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Late Stage Chronic Kidney Disease Drugs Market

• 19.1. Italy Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Late Stage Chronic Kidney Disease Drugs Market

• 20.1. Spain Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Late Stage Chronic Kidney Disease Drugs Market

• 21.1. Eastern Europe Late Stage Chronic Kidney Disease Drugs Market Overview
• 21.2. Eastern Europe Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Late Stage Chronic Kidney Disease Drugs Market

• 22.1. Russia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Late Stage Chronic Kidney Disease Drugs Market

• 23.1. North America Late Stage Chronic Kidney Disease Drugs Market Overview
• 23.2. North America Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Late Stage Chronic Kidney Disease Drugs Market

• 24.1. USA Late Stage Chronic Kidney Disease Drugs Market Overview
• 24.2. USA Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Late Stage Chronic Kidney Disease Drugs Market

• 25.1. Canada Late Stage Chronic Kidney Disease Drugs Market Overview
• 25.2. Canada Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Late Stage Chronic Kidney Disease Drugs Market

• 26.1. South America Late Stage Chronic Kidney Disease Drugs Market Overview
• 26.2. South America Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Late Stage Chronic Kidney Disease Drugs Market

• 27.1. Brazil Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Late Stage Chronic Kidney Disease Drugs Market

• 28.1. Middle East Late Stage Chronic Kidney Disease Drugs Market Overview
• 28.2. Middle East Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Late Stage Chronic Kidney Disease Drugs Market

• 29.1. Africa Late Stage Chronic Kidney Disease Drugs Market Overview
• 29.2. Africa Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Late Stage Chronic Kidney Disease Drugs Market Competitive Landscape And Company Profiles

• 30.1. Late Stage Chronic Kidney Disease Drugs Market Competitive Landscape
• 30.2. Late Stage Chronic Kidney Disease Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Johnson & Johnson
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. AbbVie Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Bayer AG
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Novartis AG
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Late Stage Chronic Kidney Disease Drugs Market Other Major And Innovative Companies

• 31.1. Sanofi SA
• 31.2. Bristol-Myers Squibb Company
• 31.3. AstraZeneca plc
• 31.4. Eli Lilly and Company
• 31.5. C.H. Boehringer Sohn AG & Co. KG
• 31.6. Amgen Inc.
• 31.7. Novo Nordisk A/S
• 31.8. Teva Pharmaceutical Industries Ltd.
• 31.9. Otsuka Pharmaceutical Co. Ltd.
• 31.10. Takeda Pharmaceutical Company Limited
• 31.11. Kyowa Kirin Co Ltd.
• 31.12. Vifor Pharma Management Ltd.
• 31.13. OPKO Health Inc.
• 31.14. Evotec SE
• 31.15. Ionis Pharmaceuticals Inc.

32. Global Late Stage Chronic Kidney Disease Drugs Market Competitive Benchmarking

33. Global Late Stage Chronic Kidney Disease Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Late Stage Chronic Kidney Disease Drugs Market

35. Late Stage Chronic Kidney Disease Drugs Market Future Outlook and Potential Analysis

• 35.1 Late Stage Chronic Kidney Disease Drugs Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Late Stage Chronic Kidney Disease Drugs Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Late Stage Chronic Kidney Disease Drugs Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer